MedTrace Logo

Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis

NCT06206083 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2024-02-28

No results posted yet for this study

Summary

Endometrial cancer (EC) is one of the most common gynecological neoplasms, being the second in incidence and third in mortality in Mexico. Recent studies show that EC molecular classification (Cancer Genome Atlas Research Network, 2013) serves to establish a more accurate prognosis in these patients and regulate therapeutic behavior in a personalized manner. However, there are no studies on EC molecular classification in Mexican women or its impact on prognosis and the possible modification of targeted treatment. The investigators will determine the molecular classification in EC by next-generation sequencing (NGS) to detect TP53 and POLE somatic mutations, and immunohistochemical detection of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3) in a cohort of patients with endometrioid-type EC, endometrioid subtype, attended at the Instituto Nacional de Cancerología - Mexico (INCan) and determine its impact on clinical prognosis.

Conditions

Interventions

GENETIC

Descriptive and analytical

Patients with EC endometroid

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • National Institute of Cancerología

    lead OTHER_GOV

Principal Investigators

  • David F Cantu-de-León, PhD · The Principal Investigator

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-11-01
Completion
2027-02-01

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06206083 on ClinicalTrials.gov